why choose us

First received: May 22, 2023

Clinical Trial: DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

Study Status: Completed

Recruit Status: RECRUITING

Condition: Small Cell Lung Carcinoma

Study Type: INTERVENTIONAL


Official Title: DAREON™-5: An Open-label, Multi-center Phase II Dose Selection Trial of Intravenous BI 764532, a DLL3-targeting T Cell Engager, in Patients With Relapsed/Refractory Extensive-stage Small Cell Lun

Brief Summary: This study is open to adults with small cell lung cancer and other neuroendocrine tumours.The study is in people with advanced cancer for whom previous treatment was not successful or no standard treatment exists.The purpose of this study is to find a suitable dose of BI 764532 that people with advanced cancer can tolerate when taken alone.2 different doses of BI 764532 are tested in this study.Another purpose is to check whether BI 764532 can make tumours shrink.BI 764532 is an antibody-like molecule…

Read more